From The Motley Fool · The Motley Fool Team · · 40s
TransMedics: 3 Key Takeaways for Long-Term Investors
TransMedics raises 2026 revenue guidance to $774 million with strong quarterly growth.
In brief
TransMedics raises 2026 revenue guidance to $774 million with strong quarterly growth. TransMedics raised 2026 revenue guidance to $774 million as third-quarter revenue reached $203 million, up 41% year over year. Originally reported by The Motley Fool.
2026 Revenue Guidance
TransMedics raised 2026 revenue guidance to $764 million to $774 million.
Third-Quarter Revenue Growth
Third-quarter revenue reached $203 million, up 41% year over year.
OCS Kidney Clinical Testing
OCS Kidney clinical testing remains on track for late 2027.
ENHANCE Heart and DENOVO Lung Programs
ENHANCE Heart and DENOVO Lung programs target 2,000 to 5,000 additional annual procedures.
What to remember
TransMedics raised 2026 revenue guidance to $774 million as third-quarter revenue reached $203 million, up 41% year over year.
